PRE-FUNDED COMMON STOCK WARRANT Surrozen, Inc.Surrozen, Inc./De • April 2nd, 2024 • Biological products, (no disgnostic substances)
THIS PREFUNDED COMMON STOCK WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Surrozen, Inc., a Delaware corporation (the “Company”), up to ______ shares of Common Stock(as subject to adjustment hereunder, the “Warrant Shares”) . The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE...Surrozen, Inc./De • April 2nd, 2024 • Biological products, (no disgnostic substances)
THIS WARRANT MAY BE SUBJECT TO FORFEITURE AND CANCELLATION AS SET FORTH HEREIN AND IN SECTION 2.3 OF THE PURCHASE AGREEMENT. IN THE EVENT THIS WARRANT IS CANCELLED PURSUANT TO THE PURCHASE AGREEMENT, IT SHALL BECOME VOID WITHOUT THE REQUIREMENT FOR SURRENDER TO THE COMPANY.
SURROZEN, INC. REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 2nd, 2024 • Surrozen, Inc./De • Biological products, (no disgnostic substances)
This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the “Purchase Agreement”).
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE...Surrozen, Inc./De • April 2nd, 2024 • Biological products, (no disgnostic substances)
THIS WARRANT MAY BE SUBJECT TO FORFEITURE AND CANCELLATION AS SET FORTH HEREIN AND IN SECTION 2.3 OF THE PURCHASE AGREEMENT. IN THE EVENT THIS WARRANT IS CANCELLED PURSUANT TO THE PURCHASE AGREEMENT, IT SHALL BECOME VOID WITHOUT THE REQUIREMENT FOR SURRENDER TO THE COMPANY.
SURROZEN, INC. SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 2nd, 2024 • Surrozen, Inc./De • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of April 1, 2024, by and between Surrozen, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE...Surrozen, Inc./De • April 2nd, 2024 • Biological products, (no disgnostic substances)
THIS WARRANT MAY BE SUBJECT TO FORFEITURE AND CANCELLATION AS SET FORTH HEREIN AND IN SECTION 2.3 OF THE PURCHASE AGREEMENT. IN THE EVENT THIS WARRANT IS CANCELLED PURSUANT TO THE PURCHASE AGREEMENT, IT SHALL BECOME VOID WITHOUT THE REQUIREMENT FOR SURRENDER TO THE COMPANY.
